市场调查报告书
商品编码
1494343
北美流动止血剂市场预测至 2028 年 - 区域分析 - 按材料、产品、应用和最终用户North America Flowable Hemostats Market Forecast to 2028 - Regional Analysis - by Material, Product, Application, and End User |
北美可流动止血剂市场预计将从2022年的4.9474亿美元成长到2028年的7.4249亿美元。
导致产品创新的研发 (R&D) 活动推动北美可流动止血剂市场
医疗保健产业对止血剂产品的需求量很大。在过去的几年中,许多止血剂产品已被开发并在多种外科手术中使用。研究人员正在进行深入的研究和开发活动,从而实现产品创新。例如,2019年12月,Ethicon(强生医疗器材公司)的新产品「SURGIFLO止血基质」。 SURGIFLOW 可流动止血产品可在手术时止血,并且比 FLOSEAL(Baxter 製造)更快。此外,2018 年 1 月,领先的止血设备开发商和行销商 Z-Medica, LLC 推出了 QuikClot Control+,它可以帮助拯救生命并满足全国各地医院未满足的需求。 QuikClot Control+ 适用于暂时控制出现 III 级或 IV 级出血的患者的内臟器官间隙出血。它甚至可以用于控制严重流血的伤口,例如手术伤口和外伤。因此,预计导致产品创新的研发活动将在预测期内推动整个可流动止血剂市场的成长。
北美可流动止血剂市场概况
医疗保健产业对止血剂产品的需求量很大。在过去的几年中,许多止血剂产品已被开发并在多种外科手术中使用。研究人员正在进行深入的研究和开发活动,从而实现产品创新。例如,2019年12月,Ethicon(强生医疗器材公司)的新产品「SURGIFLO止血基质」。 SURGIFLOW 可流动止血产品可在手术时止血,并且比 FLOSEAL(Baxter 製造)更快。此外,2018 年 1 月,领先的止血设备开发商和行销商 Z-Medica, LLC 推出了 QuikClot Control+,它可以帮助拯救生命并满足全国各地医院未满足的需求。 QuikClot Control+ 适用于暂时控制出现 III 级或 IV 级出血的患者的内臟器官间隙出血。它甚至可以用于控制严重流血的伤口,例如手术伤口和外伤。因此,预计导致产品创新的研发活动将在预测期内推动整个可流动止血剂市场的成长。
北美流动止血剂市场收入及 2028 年预测(百万美元)
北美流动止血剂市场细分
北美流动止血剂市场分为材料、产品、应用、最终用户和国家。
根据材料,北美流动止血剂市场分为牛明胶和猪明胶。 2022 年,牛明胶细分市场在北美流动止血剂市场中占据更大份额。
就产品而言,北美可流动止血器市场分为组合止血器、被动止血器和主动式止血器。 2022 年,组合止血剂细分市场在北美可流动止血剂市场中占据最大份额。
根据应用,北美可流动止血剂市场分为一般外科、心臟外科、血管外科、骨科外科、神经和脊椎外科等。 2022 年,一般外科细分市场在北美流动止血剂市场中占最大份额。
根据最终用户,北美可流动止血剂市场分为医院和诊所、门诊手术中心等。 2022 年,医院和诊所在北美流动止血剂市场中占据最大份额。
依国家划分,北美流动止血剂市场分为美国、加拿大和墨西哥。 2022 年,美国将主导北美流动止血剂市场。
Baxter International Inc、Ethicon (Johnson & Johnson)、Pfizer Inc、Teleflex Incorporated、3-D Matrix Medical Technology、Biom'up 和 Aegis Lifesciences 是北美流动止血剂市场上的一些领先公司。
The North America flowable hemostats market is expected to grow from US$ 494.74 million in 2022 to US$ 742.49 million by 2028. It is estimated to grow at a CAGR of 7.0% from 2022 to 2028.
Research and Development (R&D) Activities Leading to Product Innovations Fuel North America Flowable Hemostats Market
Hemostat products are high in demand in the healthcare industry. Over the past several years, many hemostat products have been developed and utilized in several surgical procedures. Researchers are carrying out intensive research and development activities resulting in product innovations. For Instance, In December 2019, Ethicon's (Johnson & Johnson Medical Device Companies) new product, "SURGIFLO Hemostatic Matrix." SURGIFLOW flowable hemostatic product stops bleeding while performing surgery and is faster than FLOSEAL (manufactured by Baxter). Furthermore, In January 2018, Z-Medica, LLC, a leading developer and marketer of hemostatic devices introduced QuikClot Control+ which can help save lives and fill the unmet need of hospitals across the country. QuikClot Control+ is indicated for temporary control of internal organ space bleeding for patients displaying class III or class IV bleeding. It may even be used to control severe bleeding wounds such as surgical wounds and traumatic injuries. Thus, research and development activities leading to product innovations are predicted to deliver an impetus for the growth of the overall flowable hemostats market during the forecast period.
North America Flowable Hemostats Market Overview
Hemostat products are high in demand in the healthcare industry. Over the past several years, many hemostat products have been developed and utilized in several surgical procedures. Researchers are carrying out intensive research and development activities resulting in product innovations. For Instance, In December 2019, Ethicon's (Johnson & Johnson Medical Device Companies) new product, "SURGIFLO Hemostatic Matrix." SURGIFLOW flowable hemostatic product stops bleeding while performing surgery and is faster than FLOSEAL (manufactured by Baxter). Furthermore, In January 2018, Z-Medica, LLC, a leading developer and marketer of hemostatic devices introduced QuikClot Control+ which can help save lives and fill the unmet need of hospitals across the country. QuikClot Control+ is indicated for temporary control of internal organ space bleeding for patients displaying class III or class IV bleeding. It may even be used to control severe bleeding wounds such as surgical wounds and traumatic injuries. Thus, research and development activities leading to product innovations are predicted to deliver an impetus for the growth of the overall flowable hemostats market during the forecast period.
North America Flowable Hemostats Market Revenue and Forecast to 2028 (US$ Million)
North America Flowable Hemostats Market Segmentation
The North America flowable hemostats market is segmented into material, product, application, end user, and country.
Based on material, the North America flowable hemostats market is bifurcated into bovine gelatin & porcine gelatin. The bovine gelatin segment held a larger share of the North America flowable hemostats market in 2022.
In terms of product, the North America flowable hemostats market is segmented into combination hemostats, passive hemostats, and active hemostats. The combination hemostats segment held the largest share of the North America flowable hemostats market in 2022.
Based on Application, the North America flowable hemostats market is categorized into general surgery, cardiac surgery, vascular surgery, orthopedic surgery, neuro and spine surgery, and others. The general surgery segment held the largest share of the North America flowable hemostats market in 2022.
Based on end user, the North America flowable hemostats market is segmented into hospitals and clinics, ambulatory surgery centers, and others. The hospitals and clinics segment held the largest share of the North America flowable hemostats market in 2022.
By country, the North America flowable hemostats market is categorized into the US, Canada, and Mexico. The US dominated the North America flowable hemostats market in 2022.
Baxter International Inc, Ethicon (Johnson & Johnson), Pfizer Inc, Teleflex Incorporated, 3-D Matrix Medical Technology, Biom'up, and Aegis Lifesciences are some of the leading companies operating in the North America North America flowable hemostats market.